{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"79","value":"125"},{"groupId":"OG001","spread":"67","value":"124"}]}],"title":"LY2523355"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"51","value":"5.0"},{"groupId":"OG001","spread":"52","value":"5.3"}]}],"title":"LSN2546307"}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Plasma Cmax following daily doses of LY2523355 on Days 1, 2, and 3 of Cycle 1 (21-day cycle).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"LY2523355: 5 milligrams/square meter/day (mg/m²/day) administered intravenously as a 1-hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle.","id":"OG000","title":"5 mg/m² LY2523355"},{"description":"LY2523355: 6 mg/m²/day administered intravenously as a one hour infusion on Days 1, 2, and 3 + pegfilgrastim on Day 4 of each 21-day cycle.","id":"OG001","title":"6 mg/m² LY253355"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants who received at least 1 dose of study drug with Cmax measure.","reportingStatus":"POSTED","timeFrame":"Day 3 of Cycle 1 (21-day cycle)","title":"Pharmacokinetics, Maximum Plasma Concentration (Cmax) of LY2523355 and Metabolite LSN2546307","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}